SLC6A3 and Parkinson disease: Overall, this study indicated that SUMOylation is a novel mechanism to regulate DAT expression and dopamine uptake in dopamine neurons, suggesting that the SUMO pathway—including SUMO1, SUMO2, Ubc9, and DAT SUMOylation—is a potential therapeutic target for PD (Cartier et al., 2019).